PDCD1 and hepatocellular carcinoma: Nonetheless, the KEYNOTE-240 phase III trial, which compared pembrolizumab (anti-PD-1) vs. best supportive care (BSC) as second line therapy in 413 HCC patients, failed to achieve a statistically significant benefit on OS and PFS [35].